Literature DB >> 31492932

Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix.

Inmaculada Nicolás1, Adela Saco2, Esther Barnadas2,3, Lorena Marimon2,3, Natalia Rakislova2,3, Pere Fusté1, Angeles Rovirosa4, Lydia Gaba5, Laura Buñesch6, Blanca Gil-Ibañez1, Jaume Pahisa1, Berta Díaz-Feijoo1, Aureli Torne1, Jaume Ordi2,3, Marta Del Pino7.   

Abstract

Human papillomaviruses (HPVs) are the causative agents of carcinoma of the uterine cervix. A number of HPV genotypes have been associated with cervical cancer and almost all tumors associated with HPV show strong p16 expression. However, there is little information on the possible impact of the HPV genotype and p16 immunostaining on the clinicopathological features or their prognostic value in cervical carcinoma. We evaluated a series of 194 patients with HPV-positive cervical cancers treated at our institution, focusing on the clinicopathological features and the relationship of the HPV genotypes and p16 immunostaining with the prognosis. A single HPV type was identified in 149 (77%) tumors, multiple HPV infection was detected in 30 cases (15%), and undetermined HPV type/s were identified in 15 (8%) carcinomas. HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18. Patients with HPV 16 and/or 18 were younger (49 ± 15 vs. 57 ± 17 years, p < 0.01) and more frequently had nonsquamous tumors than patients with other HPV types (24% [37/156] vs. 0% [0/38]; p = 0.01). Neither the HPV type nor multiple infection showed any prognostic impact. Patients with p16-negative tumors showed a significantly worse overall survival than women with p16-positive carcinomas (45 vs. 156 months, p = 0.03), although no significant differences in disease-free survival were observed. In the multivariate analysis, negative p16 immunostaining was associated with a worse overall survival together with advanced FIGO stage and lymph node metastases. In conclusion, the HPV genotype has limited clinical utility and does not seem to have prognostic value in cervical cancer. In contrast, a negative p16 result in patients with HPV-positive tumors is a prognostic marker associated with a poor overall survival.

Entities:  

Year:  2019        PMID: 31492932     DOI: 10.1038/s41379-019-0360-3

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

Review 1.  [Current WHO classification of the female genitals : Many new things, but also some old].

Authors:  Doris Mayr; Elisa Schmoeckel; Anne Kathrin Höhn; Grit Gesine Ruth Hiller; Lars-Christian Horn
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

2.  Increased miR-20b Level in High Grade Cervical Intraepithelial Neoplasia.

Authors:  Tímea Szekerczés; Ádám Galamb; Norbert Varga; Márta Benczik; Adrienn Kocsis; Krisztina Schlachter; András Kiss; Nándor Ács; Zsuzsa Schaff; Csaba Jeney; Gábor Lendvai; Gábor Sobel
Journal:  Pathol Oncol Res       Date:  2020-07-08       Impact factor: 3.201

3.  P16 and HPV Genotype Significance in HPV-Associated Cervical Cancer-A Large Cohort of Two Tertiary Referral Centers.

Authors:  Sara da Mata; Joana Ferreira; Inmaculada Nicolás; Susana Esteves; Gonçalo Esteves; Sofia Lérias; Fernanda Silva; Adela Saco; Daniela Cochicho; Mário Cunha; Marta Del Pino; Jaume Ordi; Ana Félix
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

4.  The Role of the Metabolic Parameters of 18F-FDG PET/CT in Patients With Locally Advanced Cervical Cancer.

Authors:  Dunhuang Wang; Xiaoliang Liu; Weiping Wang; Li Huo; Qingqing Pan; Xue Ren; Fuquan Zhang; Ke Hu
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244

Review 5.  Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins.

Authors:  Daria A Haręża; Jacek R Wilczyński; Edyta Paradowska
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

6.  Absence of Nuclear p16 Is a Diagnostic and Independent Prognostic Biomarker in Squamous Cell Carcinoma of the Cervix.

Authors:  Saioa Mendaza; Joaquín Fernández-Irigoyen; Enrique Santamaría; Tamara Zudaire; Rosa Guarch; David Guerrero-Setas; August Vidal; José Santos-Salas; Xavier Matias-Guiu; Karina Ausín; María José Díaz de Cerio; Esperanza Martín-Sánchez
Journal:  Int J Mol Sci       Date:  2020-03-19       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.